NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Weight Loss & Metabolic/Cagrilintide

Cagrilintide

Long-acting synthetic amylin analog in clinical development for obesity, often studied with semaglutide as the combination referred to as CagriSema.

Overview

Cagrilintide is a long-acting synthetic analog of the pancreatic hormone amylin, developed by Novo Nordisk as an investigational treatment for overweight and obesity. It is frequently studied together with the GLP-1 receptor agonist semaglutide; this combination is referred to as CagriSema.

Clinical development has progressed through randomized phase 2 and phase 3 programs in people with obesity or overweight. Regulatory status varies by jurisdiction and over time; the molecule remains an investigational agent in most markets.

Mechanism

Amylin, co-secreted with insulin, regulates food intake and gastric function through amylin receptors, complexes of the calcitonin receptor with receptor-activity-modifying proteins, including in hindbrain regions such as the area postrema.

Cagrilintide is engineered with fatty-acid acylation to bind albumin and extend its half-life, allowing once-weekly subcutaneous administration. Amylin-receptor agonism reduces appetite and slows gastric emptying.

Dosing

In clinical trials, cagrilintide is administered by subcutaneous injection once weekly, with doses escalated over the first weeks of treatment. When combined with semaglutide, both agents are given on the same weekly schedule.

  • Once-weekly subcutaneous injection in clinical protocols
  • Dose escalation during the initial weeks of treatment
  • Combination with semaglutide (CagriSema) evaluated in dedicated trials

Expected Effects

  • Dose-dependent reductions in body weight reported in phase 2 and phase 3 trials
  • Reductions in appetite and food intake reported
  • Combination with semaglutide produced larger mean weight losses than either agent alone in reported trials
  • Gastrointestinal adverse effects are the main tolerability limitation

Side Effects & Tolerability

The most common adverse events in trials are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, consistent with the amylin and incretin drug class; they are usually dose-dependent and most prominent during dose escalation.

Storage

As an investigational pharmaceutical, storage follows the clinical-trial protocol, typically refrigerated. Research-grade material should be stored per the supplier's instructions, generally frozen, desiccated, and protected from light.

Related peptides

AdipotideInvestigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.Advanced Thermogenic Master AnalogsMarketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.AMPK & mTOR Balance AnalogsCatalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.Amylin Analogs (Expanded)Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.Autophagy Enhancer Peptide AnalogsCatalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.C-Peptide AnalogsSynthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.